New combo shows promise for myeloma patients who failed earlier therapy

This study tests a combination of four drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) in people with multiple myeloma whose cancer returned or didn't respond after previous treatment with daratumumab. The goal is to see if this combo can shrink tumors more effectively than standard options. The study involves 11 participants and is currently active but not recruiting.